SCHEMBL4308068

SCHEMBL4308068

O=C(OC(Cn1ncnn1)c1ccccc1Cl)N1CCC(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
HTR2B P41595 2/20 0.38
MAPK14 Q16539 2/20 0.38
MGLL Q99685 5/20 0.37
FAAH O00519 3/20 0.36
TACR1 P25103 3/20 0.36
GHSR Q92847 1/20 0.35
GPR119 Q8TDV5 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PKM P14618 1/20 0.34
RIPK1 Q13546 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4306732 0.88 FAAH (0.47) CYP2C9CYP2C19HTR2BMAPK14FAAH
SCHEMBL13667455 0.88 FAAH (0.47) CYP2C9CYP2C19HTR2BMAPK14FAAH
SCHEMBL13667456 0.88 FAAH (0.47) CYP2C9CYP2C19HTR2BMAPK14FAAH
SCHEMBL4310470 0.87 MEN1 (0.41) CYP2C9CYP2C19HTR2BMAPK14FAAH
SCHEMBL4308566 0.87 CCR3 (0.42) CYP2C9CYP2C19HTR2BMAPK14FAAH
SCHEMBL4309032 0.87 FAAH (0.41) CYP2C9CYP2C19HTR2BMAPK14MGLL
SCHEMBL4304784 0.86 FAAH (0.41) CYP2C9CYP2C19HTR2BMAPK14FAAH
SCHEMBL4314273 0.84 SMN1; SMN2 (0.45) CYP2C9CYP2C19HTR2BMAPK14MGLL
SCHEMBL4311381 0.84 POLB (0.39) CYP2C9CYP2C19HTR2BMAPK14MGLL
SCHEMBL4304494 0.82 FAAH (0.39) CYP2C9CYP2C19HTR2BMAPK14MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879873-B1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2013-10-09 EP claimed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US claimed
US-20060258718-A1 Neurotherapeutic azole compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2006-11-16 US claimed
EP-1879873-B1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2013-10-09 EP disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
EP-1879873-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK Holdings Co., Ltd. (KR) 2008-01-23 EP disclosed
US-20060258718-A1 Neurotherapeutic azole compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2006-11-16 US disclosed
WO-2006112685-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK HOLDINGS CO., LTD. (KR) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258718-A1 Neurotherapeutic azole compounds CHRNA10, CHRNA4, CHRNA3 LIPE 3325/4885CYP2C9 145/4885CYP2C19 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.